DELFT, Netherlands,
April 17, 2024 /PRNewswire/ -- InnoGI
Technologies (formerly The TIM Company) is pleased to announce an
exciting, market-driven collaboration with Simulations Plus to
combine its TIM Technology, part of the InnoGI SurroGUT™
platform, with the GastroPlus® and ADMET
Predictor® modelling software offered by Simulations
Plus.
Understanding drug behavior following oral administration is
important because solubility and absorption profiles affect dosing
and efficacy. However, dynamic interactions between
sparingly-soluble active pharmaceutical ingredients, excipients and
the gastrointestinal (GI) environment are oversimplified in all
static in vitro dissolution models and are very difficult to
model using purely computational (in silico) approaches.
To address these challenges and reshape industry norms, we
leverage our unique combination of advanced in vitro dynamic
dissolution testing with the TIM Technology, accurately mimicking
the physiological conditions of the human GI tract, and the
GastroPlus® and ADMET Predictor® software to
deliver cutting-edge predictive models.
Behzad Mahdavi, PhD,
MBA, CEO of InnoGI Technologies, explains: "By leveraging
the unique benefits of our SurroGUT™ platform combined
with GastroPlus®, we will generate cutting-edge
predictive models and mechanistic in vitro–in
vivo correlations (IVIVCs) that far outperform current
approaches. This will improve the predictive accuracy of
physiologically-based pharmacokinetic (PBPK) models,
physiologically-based biopharmaceutics models (PBBMs), and
facilitate the development of mechanistic IVIVCs."
InnoGI Technologies is offering GastroPlus® PBPK
modelling of oral drug performance in vivo as a standalone
service, with the option to integrate in vitro release or
dissolution data for a more holistic formulation-oriented approach
using advanced TIM Technology or standard US Pharmacopeia (USP)
apparatus, and for the development of strong IVIVCs.
About SurroGUT™ and InnoGI
Technologies
InnoGI Technologies, formerly The TIM Company,
headquartered in Delft, Netherlands, is an innovative CRO and
technology provider for the pharmaceutical and food industries. Its
SurroGUT™ platform uses advanced in vitro models
such as TIM, mimicking the dynamics of the human gut. TIM
replicates dynamic pH profiles, peristalsis enzyme secretions and
digestive fluid volumes at true-to-life rates. The TIM
Technology has been used to evaluate more than 250 active
pharmaceutical ingredients in commercial drug products and has
guided clients worldwide with decision-making at different stages
of oral drug development. This reduces the number of formulation
iterations, de-risks clinical trials, and shortens the time to
market, as evidenced in more than 260 scientific publications. For
more information, visit our website
(www.innogitechnologies.com or
www.thetimcompany.com) or follow us
on LinkedIn.
About GastroPlus
GastroPlus is a sophisticated
PBPM/PBBK modeling software platform that is renowned in the
pharmaceutical, biotechnology, generics, chemicals, cosmetics and
consumer goods industries for its precision and reliability. It is
used by more than 200 companies, 350 universities, and 15
regulatory agencies worldwide, and has achieved significant
academic and industrial recognition, being cited in more than 1500
peer-reviewed publications. This high level of adoption and
citation is a testament to its utility in drug development and
regulatory submission processes, providing robust, predictive
models of drug and chemical behavior in virtual animals and
humans.
Contact:
Behzad Mahdavi
+13016934141
376219@email4pr.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/innogi-technologies-and-simulations-plus-combine-forces-to-offer-next-level-modeling-solutions-for-the-prediction-of-oral-drug-performance-302119023.html
SOURCE InnoGI Technologies